SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001819790-23-000064
Filing Date
2023-06-27
Accepted
2023-06-27 16:23:51
Documents
12
Period of Report
2023-06-22
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K tars-20230622.htm   iXBRL 8-K 37611
  Complete submission text file 0001819790-23-000064.txt   169671

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tars-20230622.xsd EX-101.SCH 1892
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tars-20230622_lab.xml EX-101.LAB 24833
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tars-20230622_pre.xml EX-101.PRE 13037
6 EXTRACTED XBRL INSTANCE DOCUMENT tars-20230622_htm.xml XML 4442
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Filer) CIK: 0001819790 (see all company filings)

IRS No.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39614 | Film No.: 231047602
SIC: 2836 Biological Products, (No Diagnostic Substances)